Mark Chao

Co-Founder at Forty Seven, Inc.

Mark Chao

Mark Chao

Co-Founder at Forty Seven, Inc.

Biography

Mark Chao founded Forty Seven, Inc. and Hepatx Corp. Currently, Dr. Chao is Vice President-Clinical Development at Forty Seven, Inc.

Overview
Career Highlights

Forty Seven, Inc.
Hepatx

RelSci Relationships

237

Contact Data
Trying to get in touch with Mark Chao? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
View Relationship Details
RelSci Relationships are individuals Mark Chao likely has professional access to. A relationship does not necessarily indicate a personal connection.
Ravindra Majeti

Founder at Forty Seven, Inc.

Relationship likelihood: Strong

Irv Weissman

Non-Resident Fellow at The Salk Institute for Biological Studies

Relationship likelihood: Strong

Mark McCamish

President, Chief Executive Officer & Director at Forty Seven, Inc.

Relationship likelihood: Strong

Jonathan MacQuitty

Venture Partner, Enterprise at Lightspeed Management Co. LLC

Relationship likelihood: Strong

Jeff Bird

Managing Director at Sutter Hill Ventures LLC

Relationship likelihood: Strong

Craig Gibbs

Chief Business Officer at Forty Seven, Inc.

Relationship likelihood: Strong

Chris H. Takimoto

Chief Medical Officer at Forty Seven, Inc.

Relationship likelihood: Strong

Ann D. Rhoads

Chief Financial Officer & Principal Accounting Officer at Forty Seven, Inc.

Relationship likelihood: Strong

Norman Kruse

Chief Patent Counsel at Forty Seven, Inc.

Relationship likelihood: Strong

Jens-Peter Volkmer

Founder & Vice President Research & Early Development at Forty Seven, Inc.

Relationship likelihood: Strong

Reveal deeper insights into your organization's relationships
with RelSci Contact Aggregator.

Empower Your Business Applications with Industry-Leading
Relationship Data from the RelSci API.

Get Contact Information on the
World's Most Influential Decision Makers.

Discover the Power of Your Network with
RelSci Premium Products.
In The News
Targeted News Service
October 10, 2019
California Institute for Regenerative Medicine: New Report Says Stem Cell Agency Produces Measurable Economic Benefits for California
GlobeNewswire
August 6, 2019
Forty Seven, Inc. Announces $6 Million in Funding from the Leukemia & Lymphoma Society TAP to Accelerate the Development of 5F9 in Myelodysplastic Syndrome
GlobeNewswire
May 15, 2019
Forty Seven, Inc. to Present Initial Safety and Efficacy Data from Phase 1b Clinical Trial of 5F9 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome at 2019 ASCO Annual Meeting
GlobeNewswire
April 26, 2019
Forty Seven Inc. Expands Collaboration with Genentech to Include Third Clinical Trial in Non-Hodgkin's Lymphoma
Trending People
Jill T. Biden
Why Prince William and Kate Might Get the COVID-19 Vaccine on Camera - New York Observer
Alex Azar
Anger in states over pace of COVID-19 vaccine allotments - The Miami Herald
Thomas H. Gardner
Here's Why Future FinTech Group Stock Came Crashing Down Today - Nasdaq
Joseph R. Biden, Jr.
Why Prince William and Kate Might Get the COVID-19 Vaccine on Camera - New York Observer
Kamala D. Harris
Why Prince William and Kate Might Get the COVID-19 Vaccine on Camera - New York Observer
Trending People
Jill T. Biden
Why Prince William and Kate Might Get the COVID-19 Vaccine on Camera - New York Observer
Alex Azar
Anger in states over pace of COVID-19 vaccine allotments - The Miami Herald
Thomas H. Gardner
Here's Why Future FinTech Group Stock Came Crashing Down Today - Nasdaq
Joseph R. Biden, Jr.
Why Prince William and Kate Might Get the COVID-19 Vaccine on Camera - New York Observer
Kamala D. Harris
Why Prince William and Kate Might Get the COVID-19 Vaccine on Camera - New York Observer
Paths to Mark Chao
Potential Connections via
Relationship Science
You
Mark Chao
Co-Founder at Forty Seven, Inc.
Education
Ph.D Cancer Biology
Class of 2011
Stanford University

Stanford University, located between San Francisco and San Jose in the heart of California's Silicon Valley, is one of the world's leading teaching and research universities. Since its opening in 1891, Stanford has been dedicated to finding solutions to big challenges and to preparing students for leadership in a complex world.

BA Biology
Class of 2004
Case Western Reserve University

Case Western Reserve University provides educational services. It offers a variety of undergraduate degree courses and graduate and professional options such as arts and sciences, dentistry, engineering, law, management, medicine, nursing, social work, and more. The firm also offers dual-degree programs. The company was founded in 1826 and is headquartered in Cleveland, OH.

Career History
Co-Founder
2014 - Current
Forty Seven, Inc.

Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA.

Co-Founder
Current
Hepatx

HepaTx is developing regenerative medicine solutions to address the need for better therapies for life-threatening liver diseases. The technology invented at Stanford University enables efficient hepatocyte production for therapeutic purposes. Its therapeutics can replace lost liver function to treat those with end-stage of liver disease, potentially saving the cost and morbidity of whole organ transplant. Hepatx was established in 2015 and is based in Palo Alto, California.

Hematology Fellow
Current
Stanford Health Care

Stanford Hospital is part of the Stanford University Medical Center along with the Lucile Packard Children's Hospital and the Stanford School of Medicine. It is world-renowned for its work in cardiovascular medicine and surgery, organ transplantation, neurology, neurosurgery, and cancer diagnosis and treatment.

Investments
Details Hidden
Forty Seven, Inc.

Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA.

Other Affiliations

Mark Chao is affiliated with Forty Seven, Inc., Hepatx, Stanford Health Care

Stay informed and up-to-date on your network with RelSci news and business alerting service. Nurture your network and further your business goals with smart intelligence on the people and companies that matter most to you.

Browse in-depth profiles on 12 million influential people and organizations. Find RelSci relationships, employment history, board memberships, donations, awards, and more.

Explore notable alumni from top universities and organizations. Expand your fundraising pool and make warm introductions to potential new business connections.

Harness the power of your relationships with RelSci Pro, the powerful platform for identifying relationship-driven business opportunities and connections that can propel your career forward.

Stay informed and up-to-date on your network with RelSci news and business alerting service. Nurture your network and further your business goals with smart intelligence on the people and companies that matter most to you.

Browse in-depth profiles on 12 million influential people and organizations. Find RelSci relationships, employment history, board memberships, donations, awards, and more.

Explore notable alumni from top universities and organizations. Expand your fundraising pool and make warm introductions to potential new business connections.

Harness the power of your relationships with RelSci Pro, the powerful platform for identifying relationship-driven business opportunities and connections that can propel your career forward.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Mark Chao. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Mark Chao's profile does not indicate a business or promotional relationship of any kind between RelSci and Mark Chao.